Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by fredgoodwinsonon Apr 13, 2020 11:00am
145 Views
Post# 30902968

RE:RE:RE:Rutherrin

RE:RE:RE:RutherrinAnd did Dr.Lilge then go on to suggest that Rutherrin would not have succeeded with a far greater margin of safety efficacy and adaptability?

If they had been so far inboard with TLD-1433 why all the subsequent flapping about in the middle of Phase 1B? Even now the sp reflects a persisting uncertainty in respect of NMIBC.

And how do they propose to treat any of the internal cancers that don`t present to a surface? If you take the paper of the 8th of April literally then PDT with TLD-1433 followed by x-ray would appear to be an option but in fact everything that they told us up until they stopped telling us anything suggests that they require Rutherrin - not TLD-1433 - for transport and accumulation.

Read the Papers and note the MULTIPLES by which Rutherrin is superior to TLD-1433 or the depths and wavelengths over which it has been effective in settings where TLD-1433 will not deliver.

Rutherrin is the single most valuable asset of this Company and its`Shareholders.
Hank - think that it probably has been animal tested but unlike TLD-1433 they have told us nothing of its`progress through toxicity and GMP over the years.







 




Bullboard Posts